Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 8/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1883584 | 0.87 | CA12 (0.46) | HPGDALDH1A1CA2CA12CA9 | |
| SCHEMBL1885392 | 0.75 | KDM4E (0.44) | ALDH1A1KDM4ECA2PPARGTSHR | |
| SCHEMBL1885070 | 0.72 | GNRHR (0.44) | ALDH1A1KDM4ELMNAPPARGTSHR | |
| SCHEMBL1882734 | 0.72 | ACSS2 (0.46) | ALDH1A1KDM4ELMNATSHRKMT2A | |
| SCHEMBL1891790 | 0.70 | PPARG (0.40) | ALDH1A1KDM4ELMNAPPARGTSHR | |
| SCHEMBL1885462 | 0.70 | KDM4E (0.39) | ALDH1A1KDM4ELMNAPPARGTSHR | |
| SCHEMBL1895599 | 0.68 | PTPN2 (0.48) | ALDH1A1KDM4ECA2LMNAPPARG | |
| SCHEMBL18955316 | 0.68 | KDM4E (0.62) | HPGDALDH1A1KDM4ECA2CA12 | |
| SCHEMBL1888311 | 0.67 | GNRHR (0.46) | ALDH1A1KDM4ETP53KMT2A | |
| SCHEMBL1885440 | 0.67 | CNR2 (0.40) | ALDH1A1KDM4ELMNAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105573-A1 | BENZIMIDAZOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF | WYETH | 2011-05-05 | — | — | US | disclosed |
| US-7732618-B2 | Benzimidazole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof | WYETH (US) | 2010-06-08 | — | — | US | disclosed |
| EP-1814865-A4 | BENZIMIDAZOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF | WYETH CORP (US) | 2009-09-02 | — | — | EP | disclosed |
| EP-1814865-A2 | BENZIMIDAZOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF | Athersys, Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20060106081-A1 | Benzimidazole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof | WYETH | 2006-05-18 | — | — | US | disclosed |
| WO-2006034418-A2 | BENZIMIDAZOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF | ATHERSYS, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106081-A1 | Benzimidazole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof | HRH2, TBXA2R, PTGDR2 | HPGD 116/4885ALDH1A1 331/4885KDM4E 4800/4885 |
| US-20110105573-A1 | BENZIMIDAZOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF | HRH2, TBXA2R, PTGDR2 | HPGD 116/4885ALDH1A1 331/4885KDM4E 4800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.